Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical activity of Apatinib in
combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line
chemotherapy in subjects with advanced EGFR wild type non-squamous non-small cell lung
cancer(NSCLC).